摘要
目的研究卡维地洛治疗无心肌梗死型冠状动脉粥样硬化性心脏病心绞痛的临床疗效。方法85例无心肌梗死型冠状动脉粥样硬化性心脏病心绞痛患者,根据治疗方法不同分为观察组(44例)和对照组(41例)。对照组患者按常规的治疗方案实施治疗,观察组患者在对照组基础上联合卡维地洛进行治疗。比较两组患者治疗效果、用药不良反应发生情况及用药前后疼痛情况和心绞痛发作频次。结果观察组治疗总有效率90.91%高于对照组的73.17%,差异具有统计学意义(P<0.05)。观察组用药不良反应发生率为11.36%,与对照组的9.76%比较,差异无统计学意义(P>0.05)。用药后,观察组口述分级评分法(VRS)评分(1.03±0.17)分低于对照组的(1.23±0.25)分,心绞痛发作频次(0.57±0.11)次/个月少于对照组的(3.56±0.71)次/个月,差异具有统计学意义(P<0.05)。结论无心肌梗死型冠状动脉粥样硬化性心脏病心绞痛患者在常规用药基础上联合卡维地洛可以在确保用药安全的前提下提升临床疗效,减轻患者的疼痛和减少心绞痛发作频次,值得推荐。
Objective To study the clinical efficacy of carvedilol on patients with angina pectoris of coronary atherosclerotic heart disease without myocardial infarction.Methods A total of 85 patients with angina pectoris of coronary atherosclerotic heart disease without myocardial infarction were divided into the observation group(44 cases)and the control group(41 cases)according to different treatment methods.The control group was treated with conventional regimen,and the observation group was treated with carvedilol on the basis of the control group.The therapeutic effect,occurrence of adverse drug reactions,pain status and frequency of angina pectoris before and after medication were compared between the two groups.Results The total effective rate of the observation group was 90.91%,which was higher than that of 73.17%of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in the observation group was 11.36%,and the difference was not statistically significant from that of 9.76%in the control group(P>0.05).After medication,the verbal rating scale(VRS)score of(1.03±0.17)points in the observation group was lower than that of(1.23±0.25)points in the control group,and the frequency of angina pectoris of(0.57±0.11)attacks/month was lower than that of(3.56±0.71)attacks/month in the control group.The differences were statistically significant(P<0.05).Conclusion For patients with angina pectoris of coronary atherosclerotic heart disease without myocardial infarction,carvedilol the application of on the basis of conventional drug use can improve clinical efficacy,reduce pain and reduce the frequency of angina pectoris on the premise of ensuring drug safety,and is worthy of recommendation.
作者
鲁敬源
LU Jing-yuan(Chifeng Municipal Hospital,Chifeng 024000,China)
出处
《中国实用医药》
2023年第20期94-97,共4页
China Practical Medicine
关键词
卡维地洛
心肌梗死
冠状动脉粥样硬化
心脏病
心绞痛
Carvedilol
Myocardial infarction
Coronary atherosclerosis
Heart disease
Angina pectoris
